Contact Us | Find An Expert

Find an Expert
a

Patient Stories

Check out our patient stories to hear from others with glaucoma from diagnosis to treatment and beyond.

Georgia

Georgia

Georgia was in danger of her vision failing due to glaucoma. The active 75-year-old from Florida knew if her cataracts and glaucoma and their associated risks went untreated, it would threaten her quality of life.

George

George

George worried that he would lose his vision when he was diagnosed with glaucoma. As a 77-year old African-American retiree with a family history of the disease, George knew his fears could end up a reality if his condition was not treated.

Deborah

Deborah

Despite wearing eyeglasses since she was a child, Deborah became worried when she noticed changes in her vision 13 years ago. After making an appointment with her eye doctor, Deborah soon received a shocking diagnosis: she was living with glaucoma.

Stay Connected

Sign up for our newsletter to receive the latest information about glaucoma, new treatments, research findings and more!

Glaukos will use the information you provide on this form to be in touch with you.

Consent(Required)
(Required)
This field is for validation purposes and should be left unchanged.

PM-US-0598

INDICATION FOR USE
The iStent inject® W Trabecular Micro-Bypass System Model G2-W is indicated for use in conjunction with cataract surgery for the reduction of intraocular pressure (IOP) in adult patients with mild-to-moderate primary open-angle glaucoma.

CONTRAINDICATIONS
The iStent inject® W is contraindicated in eyes with angle-closure glaucoma, traumatic, malignant, uveitic, or neovascular glaucoma, discernible congenital anomalies of the anterior chamber (AC) angle, retrobulbar tumor, thyroid eye disease, or Sturge-Weber Syndrome or any other type of condition that may cause elevated episcleral venous pressure.

WARNINGS
Gonioscopy should be performed prior to surgery to exclude congenital anomalies of the angle, PAS, rubeosis, or conditions that would prohibit adequate visualization of the angle that could lead to improper placement of the stent and pose a hazard.

MRI INFORMATION
The iStent inject® W is MR-Conditional, i.e., the device is safe for use in a specified MR environment under specified conditions; please see Directions for Use (DFU) label for details.

PRECAUTIONS
The surgeon should monitor the patient postoperatively for proper maintenance of intraocular pressure (IOP). The safety and effectiveness of the iStent inject® W have not been established as an alternative to the primary treatment of glaucoma with medications, in children, in eyes with significant prior trauma, abnormal anterior segment, chronic inflammation, prior glaucoma surgery (except SLT performed > 90 days preoperative), glaucoma associated with vascular disorders, pseudoexfoliative, pigmentary or other secondary open-angle glaucomas, pseudophakic eyes, phakic eyes without concomitant cataract surgery or with complicated cataract surgery, eyes with medicated intraocular pressure (IOP) > 24 mmHg or unmedicated intraocular pressure (IOP) < 21 mmHg or > 36 mmHg, or for implantation of more or less than two stents.

ADVERSE EVENTS
Common postoperative adverse events reported in the iStent inject® randomized pivotal trial included stent obstruction (6.2%), intraocular inflammation (5.7% for iStent inject® vs. 4.2% for cataract surgery only), secondary surgical intervention (5.4% vs. 5.0%) and BCVA loss ≥ 2 lines ≥ 3 months (2.6% vs. 4.2%).

CAUTION
Federal law restricts this device to sale by, or on the order of, a physician. Please see DFU for a complete list of contraindications, warnings, precautions, and adverse events.

Text Optimizer